jun-xu

CURE and HLK have partnered to form a bridge between CT and China bioscience. I really led the charge on this because of my interest in science, improving human health and, also sharing new technologies. HLK is the first Chinese member of CURE family.

I founded HLK, a pharmaceutical and biotech company with my business partner Zeng Wang a couple of years ago after we left Boehringer-Ingelheim. We are focused on developing new pharmaceutical products having formulation and delivery challenges. With our state-of-the art technologies, we can overcome deficits for compounds with poor physicochemical properties and extend patent life of pharmaceutical products – http://www.hlkpharma.com/.

As a company we form partnerships with Western and Chinese companies, as well as entrepreneurs and their startups to develop pharmaceuticals for international markets, following international standards we are open to in-licensing or joint development of drug products and biotechnologies, employing the best and economical resources available in China.

HLK is conveniently located in the High-Tech Industrial Zone of Shenzhen, Guangdong Province, China.  Shenzhen is the special economic zone and one of the top four major cities in China, and it is conveniently next to Hong Kong.

As the co-founder and President of HLK, my responsibilities are business development, strategy, customer relations, and interacting with governmental agencies and regulators.  I have been working with both Chinese and US-based companies and governments to promote mutual cooperation and business in the biotech and pharmaceutical sectors.

Prior to my current position, I have over 15 years of experience in major international pharmaceutical companies (including Novartis and Boehringer Ingelheim) in drug discovery and development. I have worked on multiple new drug targets,including target validation and assay development for new drug candidates. I also worked in drug development focusing on metabolism, development of biological assay methods and drug-drug interactions studies.

I have been interested in contributing my time to promote cultural exchange between US and China.  When I worked in Boehringer Ingelheim Pharmaceuticals, I served as a core member of the leadership team for the Asian Employee Resource Group of BI which promotes multi-cultural exchange, understanding, diversity and inclusion.

I have actively volunteered my time to initiate a number of activities to bridge the Chinese and American communities in CT. I was one of the major founders for Huaxia Chinese School of Connecticut (HXCT) as one of the 19 branches of Huaxia Chinese School (HXCS), a non-profit organization in the greater New York area serving over 7,000 students. Over the years, I served as Principal, then the Chair of the Board for HXCT and Board member and Chairperson of Huaxia School headquarter. HXCT has become a central platform of the Chinese-American communities.

In addition, I serves as the Executive Committee Member of SAPA (Sino AmericanPharmaceutical  Association)  in Connecticut.

Now, with the platforms of HLK in China and CURE in CT, I would like to facilitate communication and connections to business, technical expertise, investments and services to biotech partners and government officials. The overall goal for CURE CHINA is to enhance communication and the exchange of bioscience technologies and products betweenCT and China to benefit both communities.

Please visit our China Portal here: http://cureconnect.org/the-china-portal-a-bridge-between-ct-and-china-bioscience/.

For more information, contact me @: jun.xu@hlkpharma.com

Jun Xu